In 27 LARC patients receiving neoadjuvant chemoradiotherapy [18], MYC expression was detected in all primary tumor samples, though at highly variable levels (median expression value was 0.47 (range 0.020–4.9) relative to reference cell line expression), but was essentially not associated with patient characteristics or treatment outcome in this small cohort (Table S2). The gene discussed is MYC; the disease is neoplasm.